Influence of the Metering Chamber Volume and Actuator Design on the Aerodynamic Particle Size of a Metered Dose Inhaler

References

• Dolovich M. Characterization of medical aerosols: physical and clinical requirements for new inhalers. Aerosol Science and Technology 1995; 22: 392–399
   Web of Science ®Google Scholar
• Elvecrog J. Metered dose inhalers in a CFC-Free future. Pharmaceutical Technology Europe 1997; 9(1)52–55
   Google Scholar
• Keller M. Innovations and perpectives of metered dose inhalers in pulmonary drug delivery. International Journal of Pharmaceutics 1999; 186: 81–90
   PubMed Web of Science ®Google Scholar
• Dunbar C.A., Watkins A.P., Miller J.F. Characterization of the pMDI Spray using Numerical Methods. Proceedings of ICLASS. August, 18–221997, 876–883
   Google Scholar
• Dunbar C.A. Atomization mechanisms of the pressurized metered dose inhaler. Particulate Science and Technology 1998; 15(3–4)253–271
   Web of Science ®Google Scholar
• Polli G.P., Grim W.M., Bacher F.A., Yunker M.H. Influence of formulation on aerosol particle size. Journal of Pharmaceutical Sciences 1969; 58(4)484–486
   PubMed Web of Science ®Google Scholar
• Moren F. Drug deposition of pressurized inhalation aerosols I. Influence of actuator tube design. International Journal of Pharmaceutics 1978; 1: 205–212
   Web of Science ®Google Scholar
• Kim C.S., Trujillo D., Sackner M.A. Size aspects of metered dose inhalers. American Review of Respiratory Disease 1985; 132(1)137–142
   PubMed Web of Science ®Google Scholar
• Clark A.R. The physics of aerosol formation by MDIs—limitations of the current approach. Journal of Biopharmaceutical Sciences 1992; 3(1/2)69–76
   Google Scholar
• Brambilla G., Ganderton D., Garzia R., Lewis D., Meakin B., Ventura P. Modulation of aerosol clouds produced by pressurized inhalation aerosols. International Journal of Pharmaceutics 1999; 186(1)53–61
   PubMed Web of Science ®Google Scholar
• Dolovich M.B., Ruffin R.E., Roberts R., Newhouse M.T. Optimal delivery of aerosols from metered dose inhalers. Chest 80 (suppl) 1981; 911–915
   Google Scholar
• Meyer K.C., Auerbach W.R. Drug delivery to the lung. Polymeric Site-Specific Pharmacotherapy, A.J. Domb. John Wiley and Sons, New York 1994; 347–367
   Google Scholar
• Pritchard J.N. The influence of lung deposition on clinical response. Journal of Medicine 2001; 14(1)S19–S26
   Google Scholar
• Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. European Respiratory Journal 1998; 12: 1346–1353
   PubMed Web of Science ®Google Scholar
• Matthys H. Chlorofluorocarbon-free aerosol therapy in patients with pulmonary airflow obstruction. Respiration 1996; 63(3)321–324
   PubMedGoogle Scholar
• Milosovich S. Particle size determination via cascade impaction. Pharmaceutical Technology 1992; 16: 82–86
   Google Scholar
• Johnsen M.A. Properties of aerosol particles. Spray Technology and Marketing 1992; 2(8)46–55
   Google Scholar
• United States Pharmacopeia 25. 1969–1980, General Chapter 601 (2001)
   Google Scholar
• Ranucci J. Dynamic plume-particle size analysis using laser diffraction. Pharmaceutical Technology 1992; 16: 108–114
   Google Scholar
• Witt W., Rothele S. Laser diffraction– unlimited? Part. Syst. Charact 1996; 13: 280–286
   Web of Science ®Google Scholar
• Le Brun P.P.H., de Boer A.H., Gjaltema D., Hagedoorn P., Heijerman H.G.M., Frijlink H.W. Inhalation of tobramycin in cystic fibrosis. International Journal of Pharmaceutics 1999; 189(2)205–214
   PubMed Web of Science ®Google Scholar
• Steckel H., Muller B.W. Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227. International Journal of Pharmaceutics 1998; 173: 25–33
   Web of Science ®Google Scholar
• Warren S.J., Farr S.J. Formulation of solution metered dose inhalers and comparison with aerosols emitted from conventional suspension systems. International Journal of Pharmaceutics 1995; 124: 195–203
   Web of Science ®Google Scholar
• Evans R.M., Farr S.J., Armstrong N.A., Chatham S.M. Formulation and in vitro evaluation of pressurized inhalation aerosols containing isotropic systems of lecithin and water. Pharmaceutical Research 1991; 8(5)629–635
   PubMed Web of Science ®Google Scholar
• Newman S., Pitcairn G., Steed K., Harrison A., Nagel J. Deposition of fenoterol from pressurized metered dose inhalers containing hydrofluoroalkanes. Journal of Allergy and Clinical Immunology 1999; 104(6)S253–257
   Google Scholar
• Ranucci J.A., Cooper D., Sethachutkul K. Effect of actuator design on metered dose inhaler plume particle size. Pharmaceutical Technology 1992; 16: 84–92
   Google Scholar
• Vervaet C., Byron P.R. Drug-surfactant-propellant interactions in HFA-formulations. International Journal of Pharmaceutics 1999; 186: 13–30
   PubMed Web of Science ®Google Scholar
• Gabrio B.J., Stein S.W., Velasquez D.J. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. International Journal of Pharmaceutics 1999; 186(1)3–12
   PubMed Web of Science ®Google Scholar
• Moren F. Drug deposition of pressurized inhalation aerosols II. Influence of vapour pressure and metered volume. International Journal of Pharmaceutics 1978; 1: 213–218
   Web of Science ®Google Scholar
• Newman S.P., Moren F., Pavia D., Corrado O., Clarke S.W. The effects of changes in metered volume and propellant vapour pressure on the deposition of pressurized inhalation aerosols. International Journal of Pharmaceutics 1982; 11: 337–344
   Web of Science ®Google Scholar
• Williams R.O., III, Liu J., Koleng J.J. Influence of metering chamber volume and water level on the emitted dose of a suspension-based pMDI containing Propellant 134a. Pharmaceutical Research 1997; 14(4)438–443
   PubMed Web of Science ®Google Scholar
• Tiwari D., Goldman D., Malick W.A., Madan P.L. Formulation and evaluation of albuterol metered dose inhalers containing tetrafluoroethane (P134a), a Non-CFC Propellant. Pharmaceutical Development and Technology 1998; 3(2)163–174
   PubMedGoogle Scholar